Investigational drug · Phase 3
JK-1201I
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Glioblastoma Multiforme (GBM), Small Cell Lung Cancer.
Phase 3Last checked: Nov 20, 2026Latest source record: Sep 19, 2024 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
5
Any phase or sponsor naming "JK-1201I"
First trial start
2022
Oct 31, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "JK-1201I", any sponsor or status.
Conditions studied
As listed on its trial records.
- Glioblastoma Multiforme (GBM)
- Small Cell Lung Cancer
Approved drugs for the same conditions: Small cell lung cancer · Brain tumors (glioma) · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "JK-1201I" as an intervention, largest first.
- JK-1201I Compared with Topotecan in Patients with Relapsed Extensive Stage Small Cell Lung CancerPivotal-lookingNot yet recruiting
JenKem Technology Co., Ltd.Industry
NCT06581380 · 394 participants (planned) · Start Sep 16, 2024 · Primary completion Nov 16, 2027
Drug: JK-1201I; Topotecan · For: Small Cell Lung Cancer
JenKem Technology Co., Ltd.Industry
NCT05158491 · 63 participants (planned) · Start Nov 11, 2021 · Primary completion Dec 31, 2022
Drug: JK-1201I · For: Small Cell Lung Cancer (SCLC)
Sites: Beijing, China
JenKem Technology Co., Ltd.Industry
NCT04366648 · 25 participants · Start May 4, 2018 · Primary completion Mar 31, 2021
Drug: JK-1201I · For: Solid Tumor
Sites: Beijing, China
JenKem Technology Co., Ltd.Industry
NCT06595186 · 25 participants (planned) · Start Oct 31, 2022 · Primary completion Aug 16, 2026
Drug: JK-1201I; Temozolomide (TMZ) · For: Glioblastoma Multiforme (GBM)
Sites: Beijing, China
JenKem Technology Co., Ltd.Industry
NCT06586866 · 25 participants (planned) · Start Sep 26, 2024 · Primary completion May 26, 2026
Drug: JK-1201I · For: Triple Negative Breast Cancer (TNBC); Brain Metastasases
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Glioblastoma Multiforme (GBM)
- pegargiminaseADI-PEG 20Phase 33 trials
Polaris Group · Glioblastoma Multiforme (GBM), Hepatocellular Carcinoma, Advanced Hepatocellular Carcinoma
- CobolimabPhase 32 trials
GSK · Melanoma, Hodgkin Lymphoma, High and Low Grade Glioma
- silevertinibBDTX-1535Phase 22 trials
Black Diamond Therapeutics, Inc. · Glioblastoma (GBM), Newly Diagnosed Glioblastoma, GBM
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.